FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024539938> ?p ?o ?g. }

• W2024539938 endingPage "75" @default.
• W2024539938 startingPage "75" @default.
• W2024539938 abstract "Dear Editor, We read with interest the article. Linezolid-induced optic neuropathy by Karuppannasamy et al.[1] We congratulate the authors on highlighting a very important ocular complication due to a drug used for multi-drug resistant (MDR) tuberculosis (TB) - a condition which is becoming fairly common in our country. We also encountered a similar case in our practice recently, and we would like to highlight the similarities and differences in the two cases. Our patient was a 30-year-old male who was on treatment for MDR chest TB for the last 9 months with linezolid (600 mg/day), kanamycin 750 mg/day, injection streptomycin and (other drugs). He presented with blurred vision in both eyes for the last 1 month. His vision was counting fingers at 3 m, < N36 and 20/80, N18 in the right and left eye, respectively. Anterior segment examination showed no abnormality, and there was no relative afferent pupil defect. Fundus examination was normal. Color vision was grossly abnormal with Ishiharas charts. There was no disc edema. He was under treatment for peripheral neuropathy for the last 2 months (surprisingly linezolid was not stopped – even by the neurologist). He had significant gait abnormalities and sensory ataxia. Perimetry showed generalized field loss in right eye with a prominent field loss superiorly [Fig. 1]. Reliability was poor. Left eye perimetry showed a superior field loss also involving the center [Fig. 2]. The field defects are very similar to the ones reported by the authors. Are we seeing a pattern to the field loss due to linezolid? Toxic neuritis usually results in central or centro cecal field defects.[2] Is it possible that linezolid induced toxic neuritis produces superior field defects in addition to central or centro cecal defects?Figure 1: Right eye perimetryFigure 2: Left eye perimetryLinezolid was stopped. The vision gradually improved to 20/80, N18 and 20/30, N8 in 3 months. Perimetry also showed dramatic improvement (as shown by the authors) but similar to their case – superior defects remained [Figs. 3 and 4].Figure 3: Right eye perimetry 3 months after stopping linezolidFigure 4: Left eye perimetry 3 months after stopping linezolidSurprisingly – there was a dramatic improvement in the peripheral neuropathy as well. There was a marked improvement in the gait and sensory ataxia, which is quite contrary to the reports in the literature.[3] Comparing the two cases – both showed striking similarities in superior field defects, which improved dramatically after stopping the drug, but the superior defects persisted even at 3 months follow-up. This leads us to hypothesize that linezolid induced optic neuropathy produces superior field defects besides central ones although several more cases will have to be studied. Our patient showed improvement in peripheral neuropathy, which is contrary to what has been reported in literature, which encourages us to state that peripheral neuropathy, just like optic neuropathy is reversible – though at varying levels, which is not surprising as the cause of the two condition is one and the same.[4]" @default.
• W2024539938 created "2016-06-24" @default.
• W2024539938 creator A5020810487 @default.
• W2024539938 creator A5080145022 @default.
• W2024539938 date "2015-01-01" @default.
• W2024539938 modified "2023-10-16" @default.
• W2024539938 title "Comment on Linezolid induced optic neuropathy" @default.
• W2024539938 cites W1988279180 @default.
• W2024539938 cites W2009289882 @default.
• W2024539938 cites W2016945154 @default.
• W2024539938 cites W2095973210 @default.
• W2024539938 doi "https://doi.org/10.4103/0301-4738.151484" @default.
• W2024539938 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4363967" @default.
• W2024539938 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25686072" @default.
• W2024539938 hasPublicationYear "2015" @default.
• W2024539938 type Work @default.
• W2024539938 sameAs 2024539938 @default.
• W2024539938 citedByCount "8" @default.
• W2024539938 countsByYear W20245399382016 @default.
• W2024539938 countsByYear W20245399382017 @default.
• W2024539938 countsByYear W20245399382018 @default.
• W2024539938 countsByYear W20245399382020 @default.
• W2024539938 countsByYear W20245399382023 @default.
• W2024539938 crossrefType "journal-article" @default.
• W2024539938 hasAuthorship W2024539938A5020810487 @default.
• W2024539938 hasAuthorship W2024539938A5080145022 @default.
• W2024539938 hasBestOaLocation W20245399381 @default.
• W2024539938 hasConcept C118487528 @default.
• W2024539938 hasConcept C118552586 @default.
• W2024539938 hasConcept C134018914 @default.
• W2024539938 hasConcept C142724271 @default.
• W2024539938 hasConcept C2776058522 @default.
• W2024539938 hasConcept C2776228421 @default.
• W2024539938 hasConcept C2776391266 @default.
• W2024539938 hasConcept C2776967927 @default.
• W2024539938 hasConcept C2778233873 @default.
• W2024539938 hasConcept C2778980435 @default.
• W2024539938 hasConcept C2779159986 @default.
• W2024539938 hasConcept C2779489039 @default.
• W2024539938 hasConcept C2779901536 @default.
• W2024539938 hasConcept C2780837183 @default.
• W2024539938 hasConcept C2781069245 @default.
• W2024539938 hasConcept C2781414143 @default.
• W2024539938 hasConcept C50965678 @default.
• W2024539938 hasConcept C523546767 @default.
• W2024539938 hasConcept C54355233 @default.
• W2024539938 hasConcept C555293320 @default.
• W2024539938 hasConcept C71924100 @default.
• W2024539938 hasConcept C86803240 @default.
• W2024539938 hasConceptScore W2024539938C118487528 @default.
• W2024539938 hasConceptScore W2024539938C118552586 @default.
• W2024539938 hasConceptScore W2024539938C134018914 @default.
• W2024539938 hasConceptScore W2024539938C142724271 @default.
• W2024539938 hasConceptScore W2024539938C2776058522 @default.
• W2024539938 hasConceptScore W2024539938C2776228421 @default.
• W2024539938 hasConceptScore W2024539938C2776391266 @default.
• W2024539938 hasConceptScore W2024539938C2776967927 @default.
• W2024539938 hasConceptScore W2024539938C2778233873 @default.
• W2024539938 hasConceptScore W2024539938C2778980435 @default.
• W2024539938 hasConceptScore W2024539938C2779159986 @default.
• W2024539938 hasConceptScore W2024539938C2779489039 @default.
• W2024539938 hasConceptScore W2024539938C2779901536 @default.
• W2024539938 hasConceptScore W2024539938C2780837183 @default.
• W2024539938 hasConceptScore W2024539938C2781069245 @default.
• W2024539938 hasConceptScore W2024539938C2781414143 @default.
• W2024539938 hasConceptScore W2024539938C50965678 @default.
• W2024539938 hasConceptScore W2024539938C523546767 @default.
• W2024539938 hasConceptScore W2024539938C54355233 @default.
• W2024539938 hasConceptScore W2024539938C555293320 @default.
• W2024539938 hasConceptScore W2024539938C71924100 @default.
• W2024539938 hasConceptScore W2024539938C86803240 @default.
• W2024539938 hasIssue "1" @default.
• W2024539938 hasLocation W20245399381 @default.
• W2024539938 hasLocation W20245399382 @default.
• W2024539938 hasLocation W20245399383 @default.
• W2024539938 hasLocation W20245399384 @default.
• W2024539938 hasOpenAccess W2024539938 @default.
• W2024539938 hasPrimaryLocation W20245399381 @default.
• W2024539938 hasRelatedWork W178119177 @default.
• W2024539938 hasRelatedWork W1971166592 @default.
• W2024539938 hasRelatedWork W1974401710 @default.
• W2024539938 hasRelatedWork W2072213632 @default.
• W2024539938 hasRelatedWork W2521032006 @default.
• W2024539938 hasRelatedWork W2800946343 @default.
• W2024539938 hasRelatedWork W3184607092 @default.
• W2024539938 hasRelatedWork W4223930057 @default.
• W2024539938 hasRelatedWork W4283028359 @default.
• W2024539938 hasRelatedWork W81644945 @default.
• W2024539938 hasVolume "63" @default.
• W2024539938 isParatext "false" @default.
• W2024539938 isRetracted "false" @default.
• W2024539938 magId "2024539938" @default.
• W2024539938 workType "article" @default.